Combined transarterial chemoembolization and tislelizumab for patients with unresectable hepatocellular carcinoma

doi:10.4240/wjgs.v16.i9.2829

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 16, Issue 9

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (51)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-3) series, Tables (1-3) series.

Item

Count

PDF

HTML

Figures (1-3)

Tables (1-3)

Sum=26

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

Sum=13

Sep 27, 2024 (publication date) through Sep 18, 2024

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Surgery

ISSN

1948-9366

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Gastrointest Surg. Sep 27, 2024; 16(9): 2829-2841
Published online Sep 27, 2024. doi: 10.4240/wjgs.v16.i9.2829

Open in New Tab Full Size Figure Download Figure

Figure 1 Flowchart showing the detailed patients screening process of this study. HCC: Hepatocellular carcinoma; TACE: Transarterial chemoembolization; ECOG-PS: Eastern Cooperative Oncology Group Performance Status.

Open in New Tab Full Size Figure Download Figure

Figure 2 Patient overall survival. A: Overall survival (OS); B-F: OS comparison by vascular invasion status (B), immunotherapy sequence (C), prior transarterial chemoembolization (D), combined targeted therapy (E) and treatment line of immunotherapy (F). OS: Overall survival; TACE: Transarterial chemoembolization.

Open in New Tab Full Size Figure Download Figure

Figure 3 Patient progression-free survival. A: Overall progression-free survival (PFS); B-F: PFS comparison by vascular invasion status (B), immunotherapy sequence (C), prior transarterial chemoembolization ((D), combined targeted therapy (E) and treatment line of immunotherapy (F). PFS: Progression-free survival; TACE: Transarterial chemoembolization.

Citation: Tan BB, Fu Y, Shao MH, Chen HL, Liu P, Fan C, Zhang H. Combined transarterial chemoembolization and tislelizumab for patients with unresectable hepatocellular carcinoma. World J Gastrointest Surg 2024; 16(9): 2829-2841
URL: https://www.wjgnet.com/1948-9366/full/v16/i9/2829.htm
DOI: https://dx.doi.org/10.4240/wjgs.v16.i9.2829